mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2020-2-110-116mrj-1026Research ArticleОБЗОРЫREVIEWSCOVID-19: новый вызов ревматологамCOVID-19: the new challenge for rheumatologistsБеловБ. С.BelovB. S.

Борис Сергеевич Белов

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

belovbor@yandex.ruКаратеевА. Е.KarateevA. E.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202030052020142110116Copyright © Белов Б.С., Каратеев А.Е., 20202020Белов Б.С., Каратеев А.Е.Belov B.S., Karateev A.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1026

В настоящее время инфекция, вызванная новым коронавирусом – COVID-19, рассматривается мировым сообществом как чрезвычайная ситуация глобального значения. Особенно обеспокоены этой проблемой ревматологи, поскольку пациенты с иммуновоспалительными ревматическими заболеваниями (ИВРЗ) имеют повышенный риск развития инфекционных заболеваний и получают лечение препаратами, оказывающими иммуносупрессивное действие. Применение базисных противовоспалительных препаратов и генно-инженерных биологических препаратов увеличивает частоту серьезных инфекций, но недостаточный контроль активности ИВРЗ (или его отсутствие) является еще большим фактором риска инфекционных осложнений. Кроме того, в современных условиях существенно возрастает роль вакцинации, в первую очередь против гриппа и пневмококковой инфекции, поскольку у больных с ИВРЗ риск летальных исходов от инфекций дыхательных путей достаточно высок, что весьма актуально в условиях текущей пандемии COVID-19.В статье представлены современные данные о частоте вирусных инфекций у больных с ИВРЗ, а также рассмотрены возможности применения противоревматических препаратов в терапии COVID-19.

Currently, the infection caused by the new coronavirus COVID-19 is considered by the global community as an emergency of international concern. Rheumatologists are particularly concerned about this problem, since patients with immune-mediated inflammatory rheumatic diseases (IMIRDs) are at higher risk for infectious diseases and receive immunosuppressive treatment. The use of disease-modifying antirheumatic drugs and biological agents increases the incidence of serious infections, but insufficient/no monitoring of IMIRD activity is an even greater risk factor for infectious complications. In addition, the role of vaccination mainly against influenza and pneumococcal infection is substantially increasing in modern conditions, since the risk of death from respiratory tract infections is quite high in patients with IMIRDs, which is very important in the context of the current COVID-19 pandemic.The paper presents an update on the incidence of viral infections in patients with IMIRDs and also discusses whether antirheumatic drugs can be used to treat COVID-19.

COVID-19иммуновоспалительные ревматические заболеваниянестероидные противовоспалительные препаратыгидроксихлорохинтоцилизумаббарицитинибCOVID-19immune-mediated inflammatory rheumatic diseasesnonsteroidal anti-inflammatory drugshydroxychloroquinetocilizumabbaricitinibReferencesLu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22; 395(10224):565-74. doi: 10.1016/S01406736(20)30251-8Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22; 395(10224):565-74. doi: 10.1016/S01406736(20)30251-8Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020 Mar;63(3):457-60. doi: 10.1007/s11427-020-1637-5Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020 Mar;63(3):457-60. doi: 10.1007/s11427-020-1637-5Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Biorxiv. 2020;2020(1):26.919985. doi: 10.1101/2020.01.26.919985Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Biorxiv. 2020;2020(1):26.919985. doi: 10.1101/2020.01.26.919985Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0.Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0.Seguin A, Galicier L, Boutboul D, et al. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016 May;149(5):1294-301. doi: 10.1016/j.chest.2015.11.004. Epub 2016 Jan 13.Seguin A, Galicier L, Boutboul D, et al. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016 May;149(5):1294-301. doi: 10.1016/j.chest.2015.11.004. Epub 2016 Jan 13.Liu T, Zhang J, Yang Y, et al. The potential role of interleukin 6 in monitoring severe case of coronavirus disease. medRxiv; 2020. doi: 10.1101/2020/03/01/20029769Liu T, Zhang J, Yang Y, et al. The potential role of interleukin 6 in monitoring severe case of coronavirus disease. medRxiv; 2020. doi: 10.1101/2020/03/01/20029769Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25770. [Epub ahead of print]Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25770. [Epub ahead of print]Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 May;70(5): 785-91. doi: 10.1136/ard.2010.128637. Epub 2011 Feb 2.Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 May;70(5): 785-91. doi: 10.1136/ard.2010.128637. Epub 2011 Feb 2.Accortt NA, Lesperance T, Liu M, et al. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):679-84. doi: 10.1002/acr.23426. Epub 2018 Mar 11.Accortt NA, Lesperance T, Liu M, et al. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):679-84. doi: 10.1002/acr.23426. Epub 2018 Mar 11.Полянская МВ. Пневмония у пациентов с ревматическими заболеваниями: частота встречаемости, клиническая картина, факторы риска. Автореф. дисс. ... канд. мед. наук. Москва; 2009. 24 с. doi:10.3390/vaccines8020153Polyanskaya MV. Pneumonia in patients with rheumatic diseases: incidence, clinical presentation, risk factors. Автореф. дисс. ... канд. мед. sci. Moscow; 2009. 24 p.EULAR Guidance for patients COVID-19 outbreak. Available from: https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfmZhang J, Zeng H, Gu J, et al. Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines (Basel). 2020; 8(2):E153. doi:10.3390/vaccines8020153Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.EULAR Guidance for patients COVID-19 outbreak. Available from: https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfmFang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.Каратеев АЕ, Насонов ЕЛ, Лила АМ. Вызывают ли НПВП специфические осложнения при коронавирусной инфекции COVID-19? Научно-практическая ревматология. 2020. Available from: https://rheumatolog.su/media/media/2020/04/03/npr_2020_2.pdfFang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.Kim SY, Chang YJ, Cho HM, et al. Nonsteroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015 Sep 21;(9):CD006362. doi: 10.1002/14651858.CD006362.pub4Karateev AE, Nasonov EL, Lila AM. Do NSAIDs cause specific complications in COVID-19 coronavirus infection? Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2020. (In Russ.). Available from: https://rheumatolog.su/media/media/2020/04/03/npr_2020_2.pdfLanas A, McCarthy D, Voelker M, et al. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds – gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. Drugs R D. 2011 Sep 1; 11(3):277-88. doi: 10.2165/11593880000000000-00000Kim SY, Chang YJ, Cho HM, et al. Nonsteroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015 Sep 21;(9):CD006362. doi: 10.1002/14651858.CD006362.pub4Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care. 2012 Feb 28;16(1):R33. doi: 10.1186/cc11211Lanas A, McCarthy D, Voelker M, et al. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds – gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. Drugs R D. 2011 Sep 1; 11(3):277-88. doi: 10.2165/11593880000000000-00000Voiriot G, Philippot Q, Elabbadi A, et al. Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in CommunityAcquired Pneumonia in Adult and Pediatric Patients. J Clin Med. 2019 Jun 3;8(6). pii: E786. doi: 10.3390/jcm8060786Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care. 2012 Feb 28;16(1):R33. doi: 10.1186/cc11211Drewry A, Ablordeppey E, Murray E, et al. Antipyretic Therapy in Critically Ill Septic Patients: A Systematic Review and Meta-Analysis. Crit Care Med. 2017 May; 45(5):806-13. Published online 2017 Apr 14. doi: 10.1097/CCM.0000000000002285Voiriot G, Philippot Q, Elabbadi A, et al. Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in CommunityAcquired Pneumonia in Adult and Pediatric Patients. J Clin Med. 2019 Jun 3;8(6). pii: E786. doi: 10.3390/jcm8060786Schenfeld J, Iles J, Trivedi M, Accortt NA. Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis. Rheumatol Int. 2017 Jul;37(7):1075-82. doi: 10.1007/s00296-017-3679-4. Epub 2017 Mar 2.Drewry A, Ablordeppey E, Murray E, et al. Antipyretic Therapy in Critically Ill Septic Patients: A Systematic Review and Meta-Analysis. Crit Care Med. 2017 May; 45(5):806-13. Published online 2017 Apr 14. doi: 10.1097/CCM.0000000000002285Ni YN, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and metaanalysis. Crit Care. 2019 Mar 27; 23(1):99. doi: 10.1186/s13054-019-2395-8Schenfeld J, Iles J, Trivedi M, Accortt NA. Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis. Rheumatol Int. 2017 Jul;37(7):1075-82. doi: 10.1007/s00296-017-3679-4. Epub 2017 Mar 2.World Health Organization. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019nCoV) Infection is Suspected: Interim Guidance. 2020.Ni YN, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and metaanalysis. Crit Care. 2019 Mar 27; 23(1):99. doi: 10.1186/s13054-019-2395-8Насонов ЕЛ, Лила АМ, Мазуров ВИ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные (аутоиммунные) ревматические заболевания. Проект рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России». Available from: https://rheumatolog.ru/sites/default/files/klinicheskie_rekomendacii_koronavirusnaya_bolezni_i_rz_poslednyaya_versiya_0.pdfWorld Health Organization. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019nCoV) Infection is Suspected: Interim Guidance. 2020.Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenzalike symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(5): 359-65. doi: 10.3109/03009742.2012.670729Nasonov EL, Lila AM, Mazurov VI, et al. Coronavirus disease 2019 (COVID-19) and immuno-inflammatory (autoimmune) rheumatic diseases. Draft recommendations of the all-Russian public organization «Association of rheumatologists of Russia».. Available from: https://rheumatolog.ru/sites/default/files/klinicheskie_rekomendacii_koronavirusnaya_bolezni_i_rz_poslednyaya_versiya_0.pdfBello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299-306. doi: 10.4081/reumatismo.2012.299Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenzalike symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(5): 359-65. doi: 10.3109/03009742.2012.670729Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020 May;79(5):667-8. doi: 10.1136/annrheumdis-2020-217424Bello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299-306. doi: 10.4081/reumatismo.2012.299Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8; 323(1):264-8.Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020 May;79(5):667-8. doi: 10.1136/annrheumdis-2020-217424Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2011 Sep;11(9):677-83. doi: 10.1016/S1473-3099(11)70065-2. Epub 2011 May 5.Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8; 323(1):264-8.Roques P, Thiberville SD, DupuisMaguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses. 2018 May 17; 10(5). pii: E268. doi: 10.3390/v10050268Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2011 Sep;11(9):677-83. doi: 10.1016/S1473-3099(11)70065-2. Epub 2011 May 5.Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69.Roques P, Thiberville SD, DupuisMaguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses. 2018 May 17; 10(5). pii: E268. doi: 10.3390/v10050268Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12:105938. doi: 10.1016/j.ijantimicag.2020.105938. [Epub ahead of print].Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69.Savarino A, Trani LD, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006 Feb;6(2): 67-9.Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12:105938. doi: 10.1016/j.ijantimicag.2020.105938. [Epub ahead of print].Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID19: results of a randomized clinical trial. medRxiv. 2020. doi: 10.1101/2020.03.22.20040758Savarino A, Trani LD, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006 Feb;6(2): 67-9.Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-3. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID19: results of a randomized clinical trial. medRxiv. 2020. doi: 10.1101/2020.03.22.20040758Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237. doi:10.1093/cid/ciaa237. [Epub ahead of print]Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-3. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;S08839441(20)30390-7. doi: 10.1016/j.jcrc.2020.03.005Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237. doi:10.1093/cid/ciaa237. [Epub ahead of print]Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020; 369:m1432. doi:10.1136/bmj.m1432Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;S08839441(20)30390-7. doi: 10.1016/j.jcrc.2020.03.005Shah S, Das S, Jain A, et al. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19) [published online ahead of print, 2020 Apr 13]. Int J Rheum Dis. 2020 Apr 13. doi: 10.1111/1756-185X.13842. [Epub ahead of print]Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020; 369:m1432. doi:10.1136/bmj.m1432Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016;44(2): 275-281. doi: 10.1097/CCM.0000000000001402Shah S, Das S, Jain A, et al. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19) [published online ahead of print, 2020 Apr 13]. Int J Rheum Dis. 2020 Apr 13. doi: 10.1111/1756-185X.13842. [Epub ahead of print]Xu X, Han M, Li T, et al. Effective treatment os severe COVID-19 patients with tocilizumab. ChinaXiv: 20200300026. 2020.Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016;44(2): 275-281. doi: 10.1097/CCM.0000000000001402Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS). Available from: https://clinicaltrials.gov/ct2/show/NCT04306705Xu X, Han M, Li T, et al. Effective treatment os severe COVID-19 patients with tocilizumab. ChinaXiv: 20200300026. 2020.Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04317092Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS). Available from: https://clinicaltrials.gov/ct2/show/NCT04306705Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis (COVIDOSE). Available from: https://clinicaltrials.gov/ct2/show/NCT04331795Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04317092Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04315298Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis (COVIDOSE). Available from: https://clinicaltrials.gov/ct2/show/NCT04331795Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 5 (08.04.2020) Available from: https://www.rosminzdrav.ru/ministry/med_covid19Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04315298«Р-Фарм» запустил КИ препаратов от коронавирусной инфекции. Available from: https://vademec.ru/news/2020/04/06/r-farmnachal-klinicheskie-ispytaniya-dvukh-svoikhpreparatov-ot-koronavirusnoy-infektsii/Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 5 (08.04.2020). Available from: https://www.rosminzdrav.ru/ministry/med_covid19Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052«R-Pharm» launched clinical trials of drugs for coronavirus infection. Available from: https://vademec.ru/news/2020/04/06/r-farmnachal-klinicheskie-ispytaniya-dvukh-svoikhpreparatov-ot-koronavirusnoy-infektsii/Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224): 565-74. doi: 10.1016/S0140-6736(20)30251-8Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052Bekerman E, Neveu G, Shulla A, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017; 127(4):1338-52. doi: 10.1172/JCI89857Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224): 565-74. doi: 10.1016/S0140-6736(20)30251-8Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Bekerman E, Neveu G, Shulla A, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017; 127(4):1338-52. doi: 10.1172/JCI89857Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-wRichardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Kelesidis T, Mastoris I, Metsini A, Tsiodras S. How to approach and treat viral infections in ICU patients. BMC Infect Dis. 2014 Nov 28;14:321. doi: 10.1186/14712334-14-321Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-wFavalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30262-0. doi: 10.1016/S1473-3099(20)30262-0. [Epub ahead of print]Kelesidis T, Mastoris I, Metsini A, Tsiodras S. How to approach and treat viral infections in ICU patients. BMC Infect Dis. 2014 Nov 28;14:321. doi: 10.1186/14712334-14-321Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30262-0. doi: 10.1016/S1473-3099(20)30262-0. [Epub ahead of print]Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30262-0. doi: 10.1016/S1473-3099(20)30262-0. [Epub ahead of print]

The authors declare that there are no conflicts of interest present.